Guerbet (XPAR:GBT) Long-Term Debt: €381.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:GBT Guerbet SA XPAR:GBT
62 GF Score
Price €9.10
GF Value €19.58
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Guerbet Long-Term Debt?

Guerbet XPAR:GBT +4.24% 62 Long-Term Debt is €381.6 Mil as of Dec. 2025. GuruFocus rates XPAR:GBT with a GF Score™ of 62/100 and a GF Value™ of €19.58 (Possible Value Trap). The stock has 5 warning signs investors should review.

Guerbet's Long-Term Debt for the quarter that ended in Dec. 2025 was €381.6 Mil.

Guerbet's quarterly Long-Term Debt increased from Dec. 2024 (€338.1 Mil) to Jun. 2025 (€340.1 Mil) and increased from Jun. 2025 (€340.1 Mil) to Dec. 2025 (€381.6 Mil).

Guerbet's annual Long-Term Debt declined from Dec. 2023 (€360.5 Mil) to Dec. 2024 (€338.1 Mil) but then increased from Dec. 2024 (€338.1 Mil) to Dec. 2025 (€381.6 Mil).

Guerbet  (XPAR:GBT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Guerbet Long-Term Debt Related Terms

Guerbet Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Guerbet's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guerbet Long-Term Debt Chart

Guerbet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 288.48 265.05 360.52 338.06 381.64

Guerbet Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360.52 362.48 338.06 340.14 381.64
XPAR:GBT
62GF Score
Guerbet SA XPAR:GBT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €381.6 Mil mean?
Guerbet (XPAR:GBT) has a Long-Term Debt of €381.6 Mil as of Dec. 2025.
Is Guerbet's Long-Term Debt too high?
Guerbet's current Long-Term Debt is €381.6 Mil. Overall, Guerbet has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Guerbet's Long-Term Debt compare to ABT and SYK?
Guerbet's Long-Term Debt of €381.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Guerbet's current Long-Term Debt is €381.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guerbet stock overvalued right now?
Based on GuruFocus' analysis, Guerbet (XPAR:GBT) is currently considered Possible Value Trap. The stock's GF Value™ is €19.58, compared to a current price of €9.10 — trading 53.5% below its estimated fair value. The current Long-Term Debt is €381.6 Mil. Guerbet's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Guerbet (XPAR:GBT), the current Long-Term Debt is €381.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guerbet (XPAR:GBT) Overvalued in 2026?

Based on GuruFocus' analysis, Guerbet stock appears to be undervalued. The current stock price of €9.10 is trading 53.5% below its estimated GF Value™ of €19.58. GuruFocus considers Guerbet to be Possible Value Trap.

Key valuation signals for XPAR:GBT:

  • Long-Term Debt: €381.6 Mil
  • GF Value™: €19.58 vs. price of €9.10 (53.5% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the XPAR:GBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guerbet Business Description

Other Exchanges 0ELV:UK4G8:Germany
Address 15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
62GF Score

Get the complete analysis for XPAR:GBT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.10
Price
€19.58
GF Value